180results about "Dipeptides" patented technology

The invention relates to coacervate-forming polymers having defined structural formulae. The invention also relates solutions comprising the coacervate-forming polymers and methods of making solutions comprising the coacervate-forming polymers. The invention also relates to polymer coacervates, comprising the coacervate-forming polymers within the coacervates, including polymer coacervates comprising cargo compounds, and methods for making such polymer coacervates. The coacervates of the invention are capable of penetrating into cells and thereby delivering cargo compounds into cells. The invention further relates to compositions, including pharmaceutical compositions, comprising the polymer coacervates. The invention also relates to uses of the coacervate-forming polymers, including medical uses.

The present disclosure provides protein degradation targeting chimeras comprising (i) a benzo[c][l,2,5]thiadiazolyl-based targeting ligand capable of binding to toxic peptides and / or protein aggregates (e.g., alpha-synuclein fibrils, amyloid plaques, and / or tau protein tangles) in brain tissue for degradation; (ii) a ubiquitin ligase recruiting ligand; and (iii) a linker between (i) and (ii). These protein degradation targeting chimeras are useful, for example, in the treatment of neurodegenerative disorders such as Parkinson’s disease (PD), multiple system atrophy (MSA), and Lewy body dementia.

The present invention relates to salts of dipeptides and their use in cell culture.The present invention further relates to a culture medium for culturing cells, preferably plant cells, animal cells or mammalian cells, and the use of the culture medium of the present invention, as well as to a method for producing a cell culture product.

The present invention relates to an antibody conjugate that is particularly suitable for targeting Trop-2 expressing cells, especially tumor cells. The antibody conjugate according to the invention has the structure (1), where AB is an antibody capable of targeting Trop-2 expressing tumors, L is a linker connecting Z to D, Z is a connecting group, and L 6 -GlcNAc(Fuc) w -(G) j -S-(L 7 ) w’ -, in which G is a monosaccharide, j is an integer ranging from 0 to 10, S is a sugar or a sugar derivative, GlcNAc is N-acetylglucosamine, Fuc is fucose, w is 0 or 1, w' is 0, 1, or 2, and L 7 is -N(H)C(O)CH2-, -N(H)C(O)CF2-, or -CH2-, D is exatecan, b is 0 or 1, x is 1 or 2, and y is 1, 2, 3, or 4. The present invention further relates to methods for preparing the antibody conjugates of structure (1) and applications of the antibody conjugates of structure (1).

The present disclosure relates to novel folic acid conjugates comprising 5-methyltetrahydrofolic acid, a radiometal chelator that optionally coordinates a radiometal M, and the albumin binder 5-(p-iodophenyl)pentanoate, and further provides uses of such conjugates and / or pharmaceutical compositions thereof in diagnostic imaging, radionuclide therapy, or theragnostic applications.

The present invention provides biomolecular glass and its use. The biomolecular glass is obtained by volatilizing a solvent from a solution of biomolecular raw materials, the solution of biomolecular raw materials comprising biomolecular raw materials, a modifier, and a solvent. The biomolecular raw materials include natural amino acids, peptides, amino acid derivatives, peptide derivatives, or mixtures of two or more of the above. The soluble biomolecular glass of the present invention has excellent biocompatibility, high light transmittance, good mechanical strength, flexible processability, and biodegradability, and can be processed into implantable or non-implantable medical materials and / or devices, fillers and stent materials, electronic sensing materials and / or devices, temporary electronic materials and / or devices, etc., and can be decomposed by living organisms or nature, with decomposition products being non-contaminating.

Novel compounds that act as inhibitors of alpha4beta7 integrin are disclosed. Pharmaceutical compositions and methods of use of inhibitors of [alpha] 4 [beta] 7 integrin are disclosed. In particular, methods of using the [alpha] 4 [beta] 7 inhibitors in the treatment of diseases or conditions associated with inflammatory bowel diseases, including ulcerative colitis and Crohn's disease.

The objective of this invention is to provide a highly safe, long-term-use, and excellent food-derived Netrin-1 production promoter. [Solution] White fungus exhibits excellent Netrin-1 production-promoting activity, and the combination of white fungus and imidazole dipeptide showed a particularly remarkable Netrin-1 production-promoting activity compared to white fungus and imidazole dipeptide alone. Therefore, white fungus, white fungus, and imidazole dipeptide can be used as foods, quasi-drugs, and pharmaceuticals with excellent Netrin-1 production-promoting activity.

The present invention provides an antibody-payload conjugate having a payload antibody ratio of 1. The antibody-payload conjugate has the structure (1): Formula (1) (wherein a, b, and c are each independently 0 or 1; L 1 , L 2 and L 3 is a linker; D is a payload; BM is a branching moiety; and Z is a connecting group obtainable by a cycloaddition reaction. The present invention further provides methods for preparing antibody-payload conjugates according to the invention, intermediate compounds in the preparation methods, and medical uses of antibody-payload conjugates according to the invention.

The invention provides an application of hederagenin in preparation of a medicine used as an SKP2 degradation agent, and particularly provides an application of hederagenin in preparation of a medicine used as an SKP2 degradation agent. The invention also provides a PROTAC compound, which comprises a target protein POI ligand, an E3 ubiquitin ligase ligand and a linking chain Linker, the general formula of the ligand-Linker-E3 ligase ligand is as follows: a POI ligand-Linker-E3 ligase ligand. The invention also provides a preparation method and application of the PROTAC compound. The PROTAC design based on HED improves the tumor tissue targeting property, and shows low toxicity in an in-vivo experiment. The invention provides a novel SKP2 (SKP2) degradation agent. The degradation agent is expected to be capable of efficiently inducing ubiquitination degradation of SKP2 protein, and a treatment strategy with higher potential and clinical application prospect is provided for overcoming the limitation of the prior art by enhancing the specific killing capability on SKP2 high-expression tumor cells and verifying the remarkable tumor inhibition effect and good safety of the degradation agent in an animal model.

The present invention provides a flavor enhancing composition that can enhance a flavor of a food product when blended with the aforesaid food product, a method for producing the same, and a method for enhancing a flavor of a food product. A first embodiment of the present invention relates to a flavor enhancing composition containing one or more heat-treated spices selected from cumin, paprika, asafoetida and mustard seed. A second embodiment of the present invention relates to a method for producing the aforesaid flavor enhancing composition, comprising heating, under a specified condition, the one or more spices selected from cumin, paprika, asafoetida and mustard seed. A third embodiment of the present invention relates to a method for enhancing a flavor of a food product, comprising blending the aforesaid flavor enhancing composition with the food product.

This invention provides novel antibody compounds and methods for using them. [Solution] Manipulated antibody compounds and their conjugates are provided, which are useful as agents for cancer immunotherapy.

The present invention provides a composition and method for increasing muscle mass, preventing muscle atrophy, and promoting muscle growth. [Solution] In certain aspects, the disclosed composition comprises dileucine and leucine and pharmaceutically acceptable salts thereof. In certain aspects, the disclosed composition is administered to subjects in need to increase muscle mass, prevent muscle atrophy, and / or promote muscle growth.

The present invention provides a conjugate of an antibody and a functional substance, said conjugate having excellent desired properties, or a salt thereof. More particularly, the present invention provides a conjugate of an antibody and a functional substance, said conjugate containing a structural unit represented by formula (1) [wherein: Ig represents an immunoglobulin unit containing two heavy chains and two light chains and bonded to LA adjacent to Ig via thiol groups in the side chains of a plurality of cysteine residues in the two heavy chains and two light chains; HG represents a hydrophilic group or a monovalent group containing a hydrophilic group; CS represents a divalent group containing a cleavable moiety; ring A represents a divalent aromatic ring group which may have a substituent (wherein the divalent aromatic ring group constitutes a π-electron conjugated system together with the aforesaid cleavable moiety); V represents an oxygen atom, a sulfur atom or an amino(NH) group; LA and LB independently represent a divalent group; D represents a functional substance; and the average number n of the aforesaid bonds per immunoglobulin unit is 1.5 or more] or a salt thereof, and substances related thereto.

The present invention relates to certain macrocyclic compounds of formula (I) and pharma- ceutically acceptable salts thereof, which are useful for the treatment or prevention of diseases associated with and / or caused by the proteasome or immunoproteasome, selected from cancer, infectious diseases, inflammatory diseases, and autoimmune diseases. [Formula 1] TIFF2024534613001006.tif71170

[Problem] To provide a novel compound promising as a prodrug-type anticancer agent that exhibits a sufficient anticancer effect and is capable of reducing adverse effects. [Solution] A compound represented by general formula (I) or a pharmaceutically acceptable salt of the compound. Formula (I): Y-T-(X1)n

The present invention provides a RAS inhibitor that selectively binds to or selectively inhibits Ras(ON). [Solution] A compound having the structure of formula Ia, or a pharmaceutically acceptable salt thereof. JPEG2026090276000524.jpg80170

The present invention relates to: a neuropsychological function improver which contains, as an active ingredient, a dipeptide containing proline or a tripeptide containing glycine and proline; and a neuropsychological function improver which comprises a soybean peptide and / or a collagen peptide. The present invention also relates to: a pharmaceutical composition for improving a neuropsychological function or a food or beverage composition for improving a neuropsychological function, which contains the improver; and a method for preventing and / or ameliorating a condition and / or a disease associated with the deterioration in a neuropsychological function, the method comprising a step of administering the improver to a patient or a potential patient to whom the improver is needed.

The present application relates to steroid compounds and conjugates thereof, in particular to the compounds and conjugates thereof, or their tautomers, mesomers, racemates, enantiomers or diastereoisomers, or mixtures thereof, or pharma- ceutically acceptable salts thereof. The present application also relates to the preparation and use of the compounds and conjugates thereof.

The present invention relates to peptides for the treatment or prevention of nonalcoholic fatty liver disease (NAFLD), non-alcoholic fatty liver (NAFL), non-alcoholic steatohepatitis (NASH), hepatic steatosis (fatty liver), liver inflammation, cirrhosis, hepatocellular carcinoma or fibrosis, especially liver fibrosis.

To provide compounds, compositions thereof, and methods of using the same.SOLUTION: The present invention provides compounds, compositions thereof, and methods of using the same. The present invention relates to compounds and methods useful for modulating the Sestrin-GATOR2 interaction thereby selectively modulating mTORC1 activity indirectly. The invention also provides pharmaceutically acceptable compositions comprising compounds of the present invention and methods of using said compositions in the treatment of various disorders. Compounds of the present invention, and pharmaceutically acceptable compositions thereof, are useful for treating a variety of diseases, disorders or conditions, associated with mTORC1. Such diseases, disorders, or conditions include diabetes, epilepsy, neurodegeneration, immune response, suppressed skeletal muscle growth, and cellular proliferative disorders (e.g., cancer) such as those described herein.SELECTED DRAWING: None

Disclosed is an antibody-drug conjugate that binds to human oncology targets.The antibody-drug conjugate comprises an antibody or its antigen-binding fragment that is covalently linked to two anti-neoplastic drug payloads through a dual linker, where at least one of the anti-neoplastic drug payloads is a BH3 mimetic.The disclosure further relates to a method and composition for use in treating cancer by administering the antibody-drug conjugate provided herein.Also disclosed is a linker-drug conjugate that comprises at least one BH3 mimetic and a method for making it.

The present invention provides a taste-enhancing composition capable of enhancing a taste of a food product when mixed into the food product, and a method for producing the taste-enhancing composition, and a food product having an enhanced taste and a method for enhancing a taste of a food product. A first embodiment pertains to a taste-enhancing composition comprising a cyclic dipeptide. A second embodiment pertains to a method that is for producing the taste-enhancing composition and that comprises increasing the cyclic dipeptide in a spice such as coriander by heating the spice. A third embodiment pertains to a food product comprising the taste-enhancing composition. A fourth embodiment pertains to a method that is for enhancing a taste of a food product, and that comprises mixing the taste-enhancing composition into the food product.

The invention relates to a method for producing a compound of general formula I, wherein E is silicon or germanium, by reacting a compound of general formula IIa and / or a compound of general formula IIb with a compound of general formula III RR'E(NR 3 R 4 )2 (III), where E is silicon or germanium.

The invention discloses a radionuclide-labeled isoindole-piperidinedione derivative and application thereof, and the structural formula of the radionuclide-labeled isoindole-piperidinedione derivative is shown in the specification. E3 ubiquitin ligase key protein CRBN is used as a new target for nuclear medicine molecular imaging research; dynamic expression of CRBN in a tumor microenvironment is accurately described by constructing a targeted molecular probe with an isoindole-piperidinedione parent nucleus structure, imaging guidance is provided for clinically and accurately screening benefited people and predicting the therapeutic effect of targeted CRBN, and imaging examples are also provided for researching dynamic expression of other key proteins in a ubiquitination system.

Providing a novel anti-inflammatory agent. An anti-inflammatory agent containing, as an active ingredient, a dipeptide selected from (D)Ile-(D)Pro, (D)Leu-(D)Pro, (D)Pro-(D)Ile, (D)Pro-(D)Leu, (D)Val-(D)-Pro, (D)Pro-(D)Val, (D)Leu-(D)Hyp, (D)Ile-(D)Hyp, (D)Val-(D)Hyp, (D)Asp-(D)Ile, (D)Asp-(D)Val, (D)Asp-(D)Leu, (D)Asp-(D)Phe, (D)Ile-(L)Pro, (D)Leu-(L)Pro, (D)Pro-(L)Ile, (D)Pro-(L)Leu, (D)Val-(L)-Pro, (D)Pro-(L)Val, (D)Leu-(L)Hyp, (D)Ile-(L)Hyp, (D)Val-(L)Hyp, (D)Asp-(L)Ile, (D)Asp-(L)Val, (D)Asp-(L)Leu, and (D)Asp-(L)Phe.

The invention provides an MITF protein degradation agent and application thereof, and particularly provides a compound or a pharmaceutically acceptable salt thereof, or a stereoisomer or a prodrug thereof, and the compound is shown as a formula (I). The compound can degrade MITF protein in a targeted manner through a ubiquitin-proteasome way, so that the compound can be used for treating indications mediated by abnormal expression of the MITF protein.

The invention discloses hyaluronic acid modified dipeptide as well as a preparation method and application thereof, and relates to the field of cosmetic peptides. The hyaluronic acid modified cosmetic peptide has a structural formula as shown in a formula (I): M-C (I), wherein M represents sodium hyaluronate, the structure of the sodium hyaluronate is shown in the formula (II), and in the formula (II), y is a natural number larger than or equal to 1; c represents a cosmetic peptide, the cosmetic peptide comprises a polypeptide with cosmetic and / or skin care efficacy or a derivative thereof, and the polypeptide comprises a dipeptide, a tripeptide, a tetrapeptide, a pentapeptide, a hexapeptide, a heptapeptide, an octapeptide or a nonapeptide; wherein M-terminal glucuronic acid is in open-loop linkage with amino in the C structure. The hyaluronic acid modified cosmetic peptide provided by the invention not only can maintain the property of sodium hyaluronate, but also can have the functionality of polypeptide, and the stability of the prepared novel compound is obviously improved, so that the hyaluronic acid modified cosmetic peptide has a wide application prospect in the field of cosmetics / skin care products.

To provide novel antibody-drug conjugate structures.SOLUTION: The present disclosure provides antibody-drug conjugate structures, which include a cleavable linker that links the antibody to the drug and has a first cleavable moiety and a second cleavable moiety that hinders cleavage of the first cleavable moiety. The disclosure also encompasses methods of production of such conjugates, as well as methods of using the same.SELECTED DRAWING: Figure 3